Helixmith

Sunyoung Kim, CEO
Seoul, Korea and San Diego, CA
(KOSDAQ: 084990.KQ)
Helixmith is an R&D-focused biopharmaceutical company based in Seoul and San Diego, developing new and innovative biopharmaceuticals based upon its proprietary scientific platform technology to address unmet medical needs. Currently, the company is actively focusing on developing the proprietary plasmid DNA-based drug Engensis at various clinical stages in the U.S., Korea, and China for cardiovascular and neurological diseases including, but not limited to, painful DPN, diabetic foot ulcer (DFU), amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth disease (CMT). The company also has an early phase pipeline in AAV-based gene therapy and CAR-T cell therapy.
www.helixmith.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions